NICE raises cost-effectiveness threshold for the first time in 26 years

NICE QALY threshold increase — in effect from April 2026 From April 2026, NICE’s cost-effectiveness threshold has risen from £20,000–£30,000 to £25,000–£35,000 per quality-adjusted life year (QALY) gained. This is the first increase in the threshold since NICE was established. The change was linked to the UK-US Economic Prosperity Deal and forms part of a […]

NICE Technology Appraisals

NICE published TA1152 on 7 May 2026, recommending semaglutide (Wegovy) for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity (BMI ≥27 kg/m²).1 The recommendation covers adults who have had a heart attack, stroke, or symptomatic peripheral arterial disease. It is to be used alongside a reduced-calorie […]